Table 2.
Users, n |
SSRIs (N06AB) |
TCAs (N06AA) |
Others (N06AX)a |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Age (years) | Total | Men | Women | Men | Women | Pb | Men | Women | Pb | Men | Women | Pb |
18–44 | 144 | 42 | 102 | 69.1 | 73.5 | NS | 9.5 | 5.9 | NS | 38.1 | 29.4 | NS |
45–64 | 260 | 82 | 178 | 58.5 | 71.3 | <0.05 | 20.7 | 12.4 | <0.05 | 37.8 | 25.8 | <0.05 |
65–84 | 188 | 58 | 130 | 64.4 | 68.5 | NS | 10.2 | 10.8 | NS | 42.4 | 30.0 | <0.05 |
Total | 592 | 182 | 410 | 62.8 | 71.0 | <0.05 | 14.8 | 10.2 | NS | 39.3 | 28.1 | <0.01 |
ATC, Anatomical Therapeutic Chemical; NS, not significant; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
For example, serotonin–noradrenaline reuptake inhibitors, tetracyclic antidepressants.
χ2 analyses comparing men and women.